About Standard Glass Lining Technology Limited

BUSINESS OVERVIEW

Standard Glass Lining Technology is among the top five specialized engineering equipment manufacturers for the pharmaceutical and chemical sectors in India, based on revenue in Fiscal 2024. The company has in-house capabilities spanning the entire value chain, including designing, engineering, manufacturing, assembly, installation, and commissioning solutions on a turnkey basis. Its portfolio features core equipment for pharmaceutical and chemical manufacturing, categorized into:

1. Reaction Systems
2. Storage, Separation, and Drying Systems
3. Plant, Engineering, and Services, including ancillary parts.

It is also ranked among India’s top three manufacturers of glass-lined, stainless steel, and nickel alloy-based specialized engineering equipment and PTFE-lined pipelines and fittings in terms of revenue in Fiscal 2024. The company serves a diversified customer base across industries such as pharmaceuticals, chemicals, paints, biotechnology, and food and beverages. Its marquee customer list includes 30 companies from the NSE 500 index, featuring renowned names like Aurobindo Pharma, Laurus Labs, Granules India, Natco Pharma, and Suven Pharmaceuticals.

Operations are supported by eight manufacturing facilities spanning over 400,000 sq. ft., strategically located in Hyderabad, Telangana, the "Pharma Hub" of India, which contributed 40% of India’s bulk drug production in Fiscal 2024. A robust sales, service, and distribution network includes four sales offices in Vadodara, Ankleshwar, Mumbai, and Vishakhapatnam, alongside a pan-India sales presence. Internationally, the company has agency agreements for sales in Bangladesh, Russia, and resale arrangements for North America, South America, Europe, and parts of Asia and Africa.

Growth has been driven by strategic partnerships, including agreements with HHV Pumps Private Limited for vacuum pumps and Japan-based Asahi Glassplant Inc. and GL Hakko Co. Ltd for glass procurement. The exclusive collaboration with GL Hakko for manufacturing and selling shell and heat tube exchangers globally (excluding Japan) has further strengthened its market position. As of September 30, 2024, March 31, 2024, March 31, 2023 and March 31, 2022, they employed 460, 378, 307 and 250 full-time employees and 731, 823, 550 and 489 contract labourers, respectively. The Bankers to the Company are Axis Bank Limited, ICICI Bank Limited, HDFC Bank Limited, The Hongkong and Shanghai Banking Corporation Limited and RBL Bank Limited.

INDUSTRY ANALYSIS

PHARMACEUTICALS INDUSTRY
India's domestic healthcare market is growing rapidly and is projected to grow at a CAGR of 8% to 10% from FY2022-23 to FY2025-26. In addition to improving private insurance coverage and a greater willingness to spend on healthcare, government policies provide catalytic stimuli. These policies include the Ayushman Bharat Program, the Ayushman Bharat Health Infrastructure Mission, and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana.

In FY2023, India a crucial supplier of generic drug, supplied almost 40% of the total U.S. generic drug (formulation) demand and approximately 25% of the total drug demand in the United Kingdom. This success can be attributed to the advanced capabilities in formulation manufacturing, the capability to meet global standards, and governmental support.

Challenges facing India’s API and KSM (Key Starting Materials) / Drug Intermediates sector include high dependence on China for raw materials, inadequate infrastructure in select areas such as fermentation, and delays in land acquisition and environmental clearance. However, several factors, such as regulatory policies, provide stimulus to the API segment in India.

India has the highest number of FDA-approved plants for manufacturing APIs, accounting for 28% of the share in 2022, almost twice that of the U.S. and China. A high number of U.S. FDA-approved plants for API indicates the capability to serve regulated markets. India's cGMP regulations are aligned with global standards, thus making it easier for Indian manufacturers to export their drug products and substances to global destinations. Generic drugs, bulk drugs, vaccines, over-the-counter medications, contract research & manufacturing, biosimilars, APIs, and biologics are some of the key segments of the Indian pharma industry. The Indian pharma industry is known for its affordable generic drugs. The country has the most number of manufacturing facilities producing generic drugs and complying with the U.S. Food and Drug Administration (USFDA). It supplies over 50% of the global demand for various vaccines and has a network of 3000 drug companies and 10,500 manufacturing units.

Hyderabad, Telangana is the “Pharma Hub” of India. In FY 2024, Hyderabad accounted for 40.0% of the total Indian bulk drug production and 50.0% of the bulk drug exports and is considered the 'Bulk Drug Capital of India'. The Indian pharmaceutical industry is ranked 3rd globally in terms of volume and 14th in terms of value and contributes a 1.72% of the country’s GDP.

India exports to over 200 countries and a major share of the exports are being made to the following countries: U.S., UK, Brazil, Netherlands, and Russia. In FY2022-23, the U.S. dominated India’s total pharma exports with a share of 31% followed by the UK, Brazil and the Netherlands. In FY2022-23, the Drug formulations and biologicals segment had around 72.5% largest share of exports followed by Bulk drugs and drug intermediates. The Indian pharma exports increased by 9.7% to US$ 27.85 Bn in FY2023-24, from US$ 25.39 Bn in FY2022- 23.

CHEMICAL INDUSTRY
The Indian chemical industry is estimated to be worth INR 18,040 Bn as of FY2022-23. It is anticipated to increase at a yearly pace of 9–12% to reach INR27,060 Bn by FY2026-27. As per IBEF, the sector is expected to grow to INR 82,000 Bn by 2040. Indian chemical industry contributes approximately 6.6% of the country’s GDP and accounts for 15-17% of value of the India’s manufacturing sector.

In 2023, the value of the specialty chemicals segment and the commodity chemicals segment accounted for approximately 46.8% and 45.2% of the Indian chemicals industry, respectively. The growth rate of the Indian specialty chemicals segment in 2015-2020 was higher than the growth rate of the Indian commodity chemicals (10.5% vs. 8.7%). The specialty chemicals industry is expected to grow at a faster rate compared to that of overall chemical industry size in India. From FY2019-20 to FY2026-2027, the Indian specialty chemicals segment is expected to grow at a CAGR of 11.2% - from INR 6,970 Bn in FY2019-20 to INR 14,654 Bn in FY2026-27.
This will be on account of the demand for specialty chemicals from segments like agrochemicals, food additives, construction chemicals, electronic chemicals, water chemicals, polymer additives, dyes and pigments, and surfactants among others.

OVERVIEW OF GLASS LINED EQUIPMENT INDUSTRY
The Glass-Lined Equipment (GLE) industry is poised for significant growth, driven by multiple factors. GLE protects the contained media from exposure to water, other chemicals, alkalis, and corrosion, providing a desirable environment for storing the media. GLE is resistant to contamination and capable of operating in a variety of environments. Glass lining technology is extensively used in various industries for its corrosion resistance and durability. Glass-lined reactors are crucial for chemical synthesis, fermentation, and controlled reactions in the chemical and pharmaceutical sectors. They protect against corrosive chemicals and maintain substance purity. Receivers with glass lining are utilized in food and beverage, pharmaceutical, and chemical processing industries for collecting and storing materials under specific conditions. The non-reactive nature of glass lining ensures substance integrity. Glass-lined heat exchangers and equipment fittings are employed in industries requiring efficient heat transfer while preserving material integrity. Glass-lining technology offers versatile solutions for industrial processes.

The unit operations of chemical manufacturing can most simply be classified as combination (mixing), reaction, and separation. The most critical of these unit operations are reaction and separation. The following chart maps the unit operations against some examples of the equipment used to carry out these operations and the various points at which their range of products is linked to the manufacturing process of such plants.

BUSINESS STRENGTHS

1. Leading Manufacturer with Comprehensive Capabilities : Ranked among the top five specialized engineering equipment manufacturers for the pharmaceutical and chemical sectors in India by revenue in Fiscal 2024 (Source: F&S Report). The company provides end-to-end solutions, including design, engineering, manufacturing, installation, and commissioning, along with customized turnkey solutions. It is also one of the top three manufacturers of glass-lined, stainless steel, and nickel alloy equipment in India. Strategic partnerships, such as those with HHV Pumps and GL Hakko, enhance market competitiveness, scalability, and customer reach.

2. Comprehensive Product Offerings : Offers customized solutions for over 65 products across pharmaceutical and chemical industries. The portfolio includes Reaction Systems, Storage, Separation, and Drying Systems, and Plant, Engineering, and Services. Products are crafted using materials like stainless steel, nickel alloy, and mild steel, with thicknesses ranging from 1 mm to 60 mm, catering to diverse industries like food, pharmaceuticals, and fine chemicals.

3. Strategically Located Manufacturing Facilities : Operates eight advanced manufacturing facilities spanning over 400,000 sq. ft. in Hyderabad, Telangana, a hub accounting for 40% of India’s bulk drug production (Source: F&S Report). Capabilities include producing 300–350 equipment monthly, 100 reactors per month, and 9,000 units of PTFE-lined pipes and fittings per month, enabling efficient large-scale production.

4. Long-Standing Client Relationships : Boasts enduring relationships with marquee clients across pharmaceuticals and chemicals. The company serves 30 NSE 500-listed companies, including Aurobindo Pharma, Laurus Labs, and Natco Pharma, emphasizing customized solutions, technical expertise, and timely delivery.

5. Proven Track Record of Profitable Growth : Achieved a 50.45% consolidated revenue growth from Fiscal 2022 to Fiscal 2024 (Source: F&S Report), making it the fastest-growing peer company. With over 11,000 equipment delivered since its inception in 2012, growth has been bolstered by acquisitions such as Stanpumps Engineering Industries and partnerships with Asahi Glassplant Inc. and GL Hakko.

6. Experienced Leadership Team : Led by a seasoned management team with extensive expertise in pharmaceuticals, chemicals, and engineering, providing strategic insights into industry requirements. The leadership team is supported by a knowledgeable board with decades of experience.

BUSINESS STRATEGIES

1. Diversification and Portfolio Expansion : Focus on strengthening the existing product portfolio and diversifying into new high-growth and profitable product categories. Plans include setting up additional manufacturing facilities and consolidating current operations to enhance cost efficiency and expand offerings to various industries and geographies.

2. Capacity Expansion : Increase manufacturing capabilities to meet growing customer demand and support the growth of end-user industries. Expansion involves scaling production capacities for existing products and setting up new manufacturing plants.

3. Leveraging International Market Opportunities : Aim to increase revenue contribution from exports by capitalizing on growing international demand. Existing agency arrangements in Bangladesh and agreements in Russia and other global markets are being utilized to expand the export footprint across North America, South America, Europe, Asia, and Africa.

4. Inorganic Growth through Strategic Acquisitions : Pursue strategic acquisitions and alliances to create synergies and enhance capabilities, especially in the glass lining equipment and PTFE-lined pipes and fittings sectors. Recent acquisitions include Higenic Flora Polymers, Yashasve Glass Lining Industries, and C.P.K Engineers Private Limited, complementing and expanding production capabilities.

BUSINESS RISK FACTORS

1. Geographic Concentration of Manufacturing Facilities : The company’s operations are entirely dependent on its eight manufacturing facilities located in Telangana, India. These facilities are exposed to risks like industrial accidents, natural disasters, power outages, and adverse economic or political conditions, potentially disrupting operations and affecting financial performance.

2. Reliance on Limited Suppliers : Key raw materials such as stainless steel, nickel alloy, and chemicals are sourced from a limited number of suppliers. Dependency on these suppliers, many of whom must meet specific customer accreditations, limits flexibility in procurement and exposes the company to risks of supply disruptions and unfavorable pricing.

3. Customer Concentration in Pharmaceuticals and Chemicals : A majority of revenues are derived from the pharmaceutical and chemical sectors, making the company highly dependent on the trends and capital expenditures within these industries. Adverse developments in these sectors could significantly impact business performance.

4. Domestic Market Dependence : Most revenues are generated from sales within India, exposing the company to risks specific to the Indian market. Limited geographical diversification could impact profitability and growth prospects in the face of regional economic or regulatory challenges.

5. Supply Chain and Transportation Risks : Smooth operations rely on the uninterrupted supply of raw materials and timely delivery of finished products. Disruptions due to supplier failures, inadequate logistics, or external events like strikes, weather issues, and geopolitical challenges could lead to increased costs and operational delays, adversely affecting financial outcomes.

NOTE : Standard Glass Lining Technology faces significant operational risks due to its reliance on geographically concentrated manufacturing facilities, limited supplier base, customer concentration in specific industries, dependence on the Indian market, and uncertainties in raw material supply and transportation. These factors collectively expose the company to vulnerabilities that could adversely impact its business operations, financial performance, and long-term growth prospects.